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Standardization in Haematology (ICSH), by the ADAMTS13 Assay Working Group,
which comprises an international group of both clinical and laboratory experts.
The document provides recommendations on best practice for the performance of
ADAMTS13 assays in clinical laboratories. ADAMTS13 assays support the differential diagnosis of thrombotic microangiopathies and have utility in the management
of thrombotic thrombocytopenic purpura (TTP). There are three types of assay: activity, antigen and autoantibody/inhibitor assays. Methods for activity assays differ
in terms of sensitivity, specificity, precision and turnaround time. The most widely
used assays involve VWF peptide substrates and either chromogenic ELISA or FRET
techniques, although chemiluminescence assays and rapid screening tests have recently become available. Tests for autoantibodies and inhibitors allow confirmation
of acquired, immune-mediated TTP, while antigen assays may be useful in congenital
TTP and as prognostic markers. In this document, we have attempted to describe
ADAMTS13 assays and the conditions that affect them, as well as: blood collection,
sample processing, quality control, standardization and clinical utility; recognizing
that laboratories in different parts of the world have varying levels of sophistication.
The recommendations are based on expert opinion, published literature and good
clinical laboratory practice.
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1 | BAC KG RO U N D

(VWF), its major substrate.1 Secretion from the hepatic stellate cell
is thought to be the main plasma source of ADAMTS13, although

ADAMTS13 (A disintegrin and metalloprotease with a thrombo-

small quantities also appear to be produced by the vascular endo-

spondin type 1 motif, member 13) is a plasma metalloprotease

thelium, podocytes in the kidney glomeruli and it may be detect-

which is critically involved in the control of von Willebrand Factor

able in platelets. 2 VWF is released as an ultralarge molecular weight
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multimeric form (ULVWF), which is rapidly cleaved by ADAMTS13,
1

and consumptive coagulopathies, with. Guidance on the diagnosis of

resulting in progressively smaller multimers. The high shear stress

TTP, management, therapy and prophylaxis are available13,16,17 and

found in small arterioles unravels the globular form of ULVWF so

ICSH has published recommendations on schistocyte enumeration

that the metalloprotease domain of ADAMTS13 can come into

in TMA.18

close proximity with the cleavage site in the VWF A2 domain, al-

HUS9 may be subdivided into infection-associated HUS (IA-HUS)

lowing cleavage. The other domains of ADAMTS13 play a role in

and complement-mediated HUS (CM-HUS, formerly termed atyp-

the attachment and unravelling of VWF, while VWF itself induces

ical HUS). IA-HUS is typically associated with Shiga toxin-induced

conformational changes in ADAMTS13, making it fully active.3-7

bloody diarrhoea in children, which is treated with supportive care,

Thrombotic microangiopathies (TMA) are a group of disorders

and in some cases renal dialysis. CM-HUS, more common in adults,

characterized by thrombocytopenia and microangiopathic haemo-

usually results from defective regulation of the complement system

lytic anaemia (MAHA) resulting in varying degrees of organ damage;

and may sometimes show multisystem symptoms similar to TTP,

they are rare, but potentially life-threatening unless they are rec-

making the differential diagnosis difficult. Unlike TTP, ADAMTS13

ognized and treated rapidly. They include thrombotic thrombocy-

levels are usually normal in CM-HUS, although they sometimes show

8,9

a moderate reduction (30-50 IU/dL). ADAMTS13 assays are thus

but may also be secondary to cancer, viral infection (eg HIV), organ

pivotal in differentiating TTP and CM-HUS, which require different

or bone marrow transplantation, pregnancy (preeclampsia/eclamp-

treatments. Plasma exchange (PEX) and immunosuppressive agents

sia or HELLP syndrome), severe hypertension, drugs, autoimmune

are typically used for TTP8,13 while PEX and complement inhibition

10-12

disorders, sepsis and disseminated intravascular coagulation.

(eg with eculizumab) are used in CM-HUS,19 although PEX may be

In thrombotic thrombocytopenic purpura (TTP), there is a loss

used until a firm diagnosis is made.

topenic purpura (TTP) and haemolytic uraemic syndrome (HUS),

of ADAMTS13 function resulting in the prolonged circulation of

The aim of this ICSH document is to provide laboratory guidance

ULVWF, which has an increased platelet binding capacity and may

and an up-to-date summary of best practice for the validation, per-

participate in platelet aggregate formation in the microcirculation

formance, and reporting of ADAMTS13 assays. The consensus rec-

with sequestration and consequent thrombocytopenia. Blood flow

ommendations provided are based on information from peer-review

is limited, causing ischaemic organ damage, and haemolysis occurs

publications, the authors' personal experience and expert opinion,

due to red cell mechanical destruction. Elevated levels of indirect

as well as good clinical laboratory practice.

bilirubin and lactate dehydrogenase are common due to the gross
haemolysis. Diagnosis is based on the presence of thrombocytopenia and MAHA, as well as the clinical history and examination of

2 | PR E-A N A LY TI C A L VA R I A B LE S

the blood film13; additional laboratory studies are required to distinguish between different causes of TMA.

Citrated (0.109 mol/L sodium citrate) platelet-poor plasma is nor-

TTP exists in acquired, immune-mediated (iTTP) and congenital

mally used for ADAMTS13 assays. Samples should be prepared to

(cTTP) forms.14 iTTP is caused by the presence of autoantibodies to

ensure platelet depletion (<10 × 10 9/L; ie centrifugation at 2000 g

ADAMTS13, which decrease its function or increase ADAMTS13

for 15 minutes). This should be performed at room temperature

clearance from the circulation. These antibodies are heterogeneous,

(18-20°C), particularly if other haemostasis assays might be per-

varying in epitope specificity and avidity. iTTP can occur at any age,

formed, to avoid potential platelet changes and proteolytic acti-

mostly in the 3rd-5th decade of life, and is frequently associated

vation. Serum and heparinized plasma have been used and may

with infection and pregnancy, but may also occur secondary to a va-

be advantageous in certain types of assay, where high sensitivity

riety of other conditions. Patients with iTTP who enter remission

is required, with less sample dilution, and where citrate chelation

may relapse at varying intervals, most recurrences occurring during

of divalent cations interferes with the assay. However, laborato-

the first year due to the reappearance of the autoantibody, loss of

ries must validate blood collection into alternative anticoagulants

ADAMTS13 and development of ULVWF. In cTTP, which usually

before clinical application. Plasma or serum samples should be

presents in childhood, the loss of ADAMTS13 activity is caused by

rapidly removed from the cells using a plastic transfer pipette,

pathogenic genetic ADAMTS13 variants, resulting in decreased syn-

avoiding disturbance to the buffy coat and stored in appropriate

thesis, secretion, or function.

polypropylene containers.

Later onset cTTP may also occur, often during pregnancy.

ADAMTS13 is present in serum, but inaccurate activity results

ADAMTS13 assays are useful to distinguish TTP from other TMA and,

could potentially occur, due to platelet and leucocyte activation as

in the untreated patient at presentation, a severe deficiency (<10 IU/

well as ADAMTS13 degradation, by thrombin and other proteases.

dL) of ADAMTS13 activity is diagnostic for TTP.14 ADAMTS13 activ-

However, this can be effectively mitigated with protease inhibitors.

ity has been listed as a critical test.15 Plasma levels and function of

It should be noted that ADAMTS13 activity can also vary signifi-

ADAMTS13 are modulated by hepatic stellate cell damage, cytokine

cantly due to other factors, for example changes in assay buffer con-

levels and oxidation (which inhibits ADAMTS13 proteolytic activity

ditions (pH, ionic strength and surfactants) can affect ADAMTS13

and makes VWF resistant to cleavage)2; a mild to moderate reduction

activity due to allosteric mechanisms.3-6 EDTA plasma cannot be

in activity may occur in cardiovascular disease, liver disease, sepsis

used for activity assays, as it irreversibly disrupts the quaternary

|
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structure of ADAMTS13, causing false low/absent activity. In cases

• EDTA plasma is not suitable for ADAMTS13 assays.

of unexpected absence of ADAMTS13 activity, where results do not

• Samples should be centrifuged and plasma separated from the

fit the clinical picture and to exclude pre-analytical variables such

cells as rapidly as possible after blood collection to avoid in vitro

as incorrect sample type, a prothrombin time or activated partial

changes.

thromboplastin time on the sample can be helpful as grossly pro-

• Unless assays are performed immediately, plasma samples should

longed times suggest EDTA contamination or serum. Alternatively,

be stored and shipped below-40°C to avoid potential proteolysis.

as EDTA samples have markedly elevated potassium and decreased
calcium, 20 electrolyte analysis showing an abnormal sodium to potassium ratio suggests EDTA anticoagulant.

3 | A DA MT S13 A S SAYS

Blood samples should be collected with minimal stasis and processed rapidly to avoid cellular and plasma activation. Any significant

There are a variety of in-house and commercial methods for

delays in processing should be recorded and depending on the lab-

ADAMTS13 activity, antigen, inhibitors and ADAMTS13 antibody

oratory policy, added as a comment to the report. Clotted samples

assay.

or those containing clumped platelets are not suitable. Samples that
are not being assayed on the same day should be stored frozen at
below −40°C.

3.1 | Activity assays

If the samples are shipped to another site, dry ice should be
used to avoid slow thawing during transit and comparable results

The widespread use of ADAMTS13 assays has been limited by the

can then be achieved between different laboratories. 21 Although

rarity of TTP in the general population, technical difficulty of the as-

ADAMTS13 has been shown to have good stability at room tem-

says and the length of time taken to generate an assay result. 24 First

perature, 22 some of these studies have employed samples from

generation activity assays involved incubation of patient plasma

healthy normal subjects and it is not clear whether stability is good

with VWF and measurement of residual VWF by multimer electro-

in all clinical samples, particularly those with critical illness and

phoresis, 25 SDS PAGE and Western Blotting with VWF antibodies, 26

the potential for reduced plasma protease inhibitor levels. Before

Immunoradiometric assay, 27 or ristocetin cofactor assay, 28 or colla-

assay, frozen samples should be warmed to 37°C in a water bath

gen binding ELISA (CBA). 29

for 5-10 minutes, until completely thawed and mixed gently to en-

Electrophoretic detection of VWF multimers and analysis by

sure that any cryoprecipitate is dissolved. Thawing for longer than

ristocetin cofactor assay are difficult, with poor precision. Assays

this is undesirable as ADAMTS13 activity is lost after prolonged

based on residual VWF binding to collagen are also time consum-

periods at 37°C. 23

ing, but the ELISA principle allows higher throughput, with better

Icteric samples may not be suitable for some assay types (see

sensitivity and precision. However, there are numerous potential

specificity section below) due to interference in absorbance mea-

sources of error, including the use of denaturing agents that besides

surement or quenching of fluorescence signal.

unravelling VWF could alter ADAMTS13 structure and dissociate

Haemolysis is frequently seen in patients with TMA, due to

ADAMTS13 autoantibodies.

entrapment and lysis of red cells in the microcirculation. However,

Second generation activity assays employ peptide substrates

where it is due to in vitro haemolysis, for example caused by a slow

based on the ADAMTS13 cleavage site in the VWF A2 domain.

blood draw, fresh samples should be obtained. Variable ADAMTS13

These are rapid, producing results within a few hours, with high

activity may also be obtained in samples with gross lipaemia, al-

throughput and good precision. However, these assays may fail

though the exact nature of any influence of plasma lipids on activity

to detect certain inherited ADAMTS13 defects, as they measure

assays has not been investigated and might possibly vary depending

metalloprotease activity independent of exosite interactions

on the composition of the lipid.

with other VWF domains. Similar problems can occur where

Samples for TTP diagnosis are optimally collected prior to initia-

ADAMTS13 autoantibodies against these exosites exist. Elevated

tion of PEX, although samples collected early in treatment may still

endogenous VWF levels influence some assays, and increased

be informative. It is important that the laboratory has details of the

bilirubin levels can interfere in fluorescence-based techniques.

type and timing of treatment.

Some of the current activity assays show relatively poor sensitivity, which can be an issue in the clinical management of TTP.

2.1 | Consensus recommendations on sample
collection and handling for ADAMTS13 assays

The key principles of some of the activity assays have been reviewed20 ; they may be divided into assays utilizing full-length
VWF as substrate and those using peptides or fragments derived
from VWF. The details of the more popular assays are given in

• Citrated plasma (centrifuged to ensure platelet depletion) should
normally be used.
• Heparin plasma or serum samples may be used depending on the
assay type and if it is validated for these sample types.

Table 1.
The most commonly used peptide substrate assays employ a 73
amino acid peptide (VWF73), based on the sequence around the
cleavage site in the VWF A2 domain,30 although some methods use
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Some popular clinical laboratory methods for ADAMTS13 activity
Diluent; dilution
factor

VWF substrate
type

Detection; assay
type

PNP diluted in assay
buffer

5 mmol/L Tris/BSA,
pH 8
1 mmol/L Pefabloc SC
3 mmol/L BaCl2
1.5 mol/L Urea
DF: 12

Full-length
plasmaderived VWF

Residual VWF
binding to collagen,
chromogenic ELISA
End-point

LLOQ: 1%-3%
Intra-assay CV: NR
Inter-assay CV: ≤6%

PNP diluted in
ADAMTS13inactivated plasma

5 mmol/L Bis-Tris,
pH 6
1 mmol/L Pefabloc SC
25 mmol/L CaCl2
0.005% Tween-20
DF: 50

VWF73
substrate

Fluorescence
change (ex 355 nm,
em 450/460 nm)
Kinetic

LLOQ: 3%-5%
Intra-assay CV: 6%
Inter-assay CV: <10%

PNP diluted in assay
buffer

5 mmol/L Bis-Tris,
pH 6
1 mmol/L Pefabloc SC
25 mmol/L CaCl2
0.005% Tween-20
DF: 30

VWF-73
substrate

Fluorescence
change (ex 340 nm,
em 450/465 nm)
Kinetic

FRET3

LLOQ = 0.3%
Intra-assay CV = 1.8%
Inter-assay CV = 1.7%

Heparinized PNP
(minimally diluted
in assay buffer)

50 mmol/L HEPES,
pH 7.4
150 mmol/L NaCl
10 mmol/L CaCl2
1 mg/L BSA
0.05% Tween-20
protease inhibitor
cocktail and
1 mmol/L PMSF
DF: 2

rVWF71
substrate

Fluorescence
change (ex 638 nm,
em 658 nm)
Kinetic

FRET48

LLOQ = 5%
Intra-assay CV = NR
Inter-assay
CV = 5%-18%

Commercial
calibrant diluted
in ADAMTS13inactivated plasma

Undisclosed
components
DF:20

VWF86-ALEXA
substrate

Fluorescence
change (ex 485 nm,
em 530 nm)
Kinetic

Chromogenic activity
ELISA32,35,48,50

LLOQ: 0.3%-3%
Intra-assay CV: ≤5.4%
Inter-assay CV: ≤8%

Commercial
calibrant diluted in
assay buffer

Undisclosed
components
DF:31

VWF73-GST
substrate

Chromogenic
ELISA format
(anti-GST capture;
HRP conjugated
anti-N10
monoclonal Ab to
detect substrate
cleavage)
End-point

Method

Performance

Calibrant

a

CBA 29,48,60,76

LLOQ = 5%-6%
Intra-assay CV = 9%
Inter-assay CV < 15%

a

FRET30,31,52,77

a

FRET30,46,48,49,50,78

Abbreviations: Ab, antibody; CV, coefficient of variation; DF, dilution factor; em, emission; ex, excitation; GST, glutathione S-transferase; HRP
horseradish peroxidase; LLOQ, lower limit of quantitation; NR, not reported; PNP, pooled normal plasma; r, recombinant.
a

Exact detail varies between laboratories.

slightly longer peptides, modified sequences or fluorophores.31 The

substrate cleavage (eg anti-N10 antibody).32 In FRET-based assays,

peptides may contain: tags to allow their attachment to microtitre

an increased fluorescence signal occurs due to the loss of quenching

plates (eg His-tag); attached proteins to allow measurement of in-

when the peptide is cleaved and the quencher is no longer in close

tact or cleaved substrate (eg glutathione S-transferase); or have

proximity to the fluorophore. The activity ELISA has multiple steps

fluorophores (eg 2-(N-methylamino)benzoyl group) and quenchers

(incubation, washing, reagent addition, etc.) and many laboratories

(eg 2,4-dinitrophenyl group) attached adjacent to the cleavage site

have microplate readers, whereas the FRET assays can be set-up with

in the fluorescence resonance energy transfer (FRET)-based assays.

automatic reagent addition, incubation and measurement, minimizing

In chromogenic activity ELISA methods, substrate cleavage may be

hands-on time, although a fluorescence microplate reader is required.

detected by loss of signal (eg removal of GST), or the increased bind-

An ADAMTS13 activity assay based on the VWF73 peptide

ing of monoclonal antibodies against a neo-epitope generated after

and surface-enhanced laser desorption ionization time-of-flight

|
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(SELDI-TOF) mass-spectrometry has also been reported.33 Although

689

3.2 | Point of care (POC)/rapid tests

highly sensitive, instrumentation requirements make this assay impractical for clinical diagnostic use in most hospital settings.

A rapid, semi-quantitative test for ADAMTS13 activity is now com-

More recently, particle-based automated assays have been de-

mercially available,38 which utilizes a flow-through cartridge and an

veloped. An automated chemiluminescence assay utilizes a two-step

activity ELISA principle, being completed within 30 minutes, without

immunoassay involving magnetic particles coated with GST-VWF73

the need for specialized instrumentation or personnel. It has four

peptide substrate and chemiluminescent detection based on an isolu-

indicator points (zero, 10, 40 and 80 IU/dL) and in comparison with

minol labelled monoclonal antibody that reacts with the cleaved pep-

a chromogenic activity ELISA in 220 patients with suspected TMA,

tide. It is a rapid assay (33 minutes), with good sensitivity and precision,

showed 88.7% sensitivity, 90.4% specificity and 96.2% negative pre-

but only has a three point calibration curve. Although there were some

dictive value. The method is limited by its subjective visual interpre-

discrepancies compared to FRET-VWF73 and a chromogenic activity

tation and potential for interference by lipids (which might block the

ELISA, with some samples showing inter-assay disparity at normal and

device membrane), haemolysis and icterus. The test is suitable for

high activity, there was a good correlation between the assays and high

use in a POC environment as a screening tool and for the negative

agreement in classifying samples with ADAMTS13 levels below 10 IU/

exclusion of TTP. When decreased activity is detected, it should be

dL.34-36 Due to the reaction principle, these assays are not affected by

confirmed by bioassay in an accredited laboratory.

icterus, lipaemia or plasma turbidity. However, the sample size in two
of these studies was small and further evaluations may be needed before their widespread acceptance and regional regulatory bodies may

3.3 | Agreement/disparity between activity assays

require additional verification or validation procedures.
The ionic strength, pH, divalent cation and chloride ion concentra-

A number of studies21,34,35,39-52 have investigated the precision and

tions are critical in ADAMTS13 assays, and all buffers should be fresh

comparability of different ADAMTS13 activity assays, although many

in order to avoid pH changes and potential bacterial contamination.

of these have involved small sample numbers, limiting their clinical ap-

Alternatively, some buffers can be stored for extended periods lyo-

plicability. In general, these studies show that the various activity as-

philized, or prepared as stock solutions (eg 10× stock buffers) espe-

says differ in the lower limit of quantification and linear range, while

cially if filtered with a 0.22 µmol/L membrane. Beside the pH and ionic

there are clear differences for certain clinical sample types, dependent

environment, the use of denaturants and differences in sample dilution

on the exact assay comparison. CBA and peptide substrate-based as-

factor between assays might have an impact on the binding kinetics of

says are certainly disparate for samples from patients with truncated

ADAMTS13 and its autoantibodies, so that varying degrees of disso-

or mutant forms of ADAMTS13 in their plasma, although this is not

ciation could occur in different assay methods.37 Finally, some assays

surprising due to differences in the substrate length. The degree of dis-

utilize heat inactivated normal plasma (treated at 56°C for 30 minutes

crepancy may vary between different CBA methods. Differences have

to denature ADAMTS13) as a diluent, to help preserve the ADAMTS13

also been noted between methods using the same peptide substrate,

environment and allow a linear standard curve.

even in severe ADAMTS13 deficiency (<10 IU/dL). Sample collection

TA B L E 2 Potential sources of
discrepancy between activity assays

Variable

Likely sources of discrepancy

Calibrant

Normal plasma or rADAMTS13

Diluent

Inactivated plasma, buffer, pH and ionic strength

Dilution factor

Immune complex dissociation (causes falsely increased activity)

Reagents

Denaturants may cause Immune complex dissociation37 (causes
falsely higher activity)

Substrate type

Peptide length and sequence (influences sensitivity to defects
involving the distal ADAMTS13 domains)

Interfering substances

Plasma colour (icterus, haemolysis, etc.) may influence FRET
assays (causing false lower activity), but causative substances
are washed away in CBA and chromogenic assays54,55

Haemoglobin

Increased plasma haemoglobin can protect VWF from
ADAMTS13 cleavage3,57,58 (reduced activity), but may have
less effect on peptide substrates (higher values)

Anti-ADAMTS13 specificity

Antibody population may affect ADAMTS13 interaction sites
present on VWF (causing reduced activity), but not smaller
peptide substrates (which may give higher values)

ADAMTS13 mutants and
truncated forms

May affect ADAMTS13 interaction sites present on VWF
(causing reduced activity), but not smaller peptide substrates
(which may give higher values)

690
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and handling differences may contribute to these changes as well as a

to overcome the problems of plasma colour, icterus and haemolysis

variety of in vivo and in vitro factors (Table 2). The results of these stud-

(see below) by utilizing fluorophores with different absorbance and

ies emphasize the need for standardization and further assay devel-

emission wavelengths.3,5

opment. When choosing which ADAMTS13 assay to set up, selection
will depend on local circumstances (including frequency and number
of samples, required turnaround time, budget, available equipment and

3.6 | Specificity

expertize). It is clear that it is important to use the same ADAMTS13
assay in a given patient when managing treatment.

In assays using full-length VWF, it must be high purity, containing
all normal multimer sizes and free of ADAMTS13 contamination.

3.4 | Standardization and calibration

This may be checked by performing assay blanks and by measuring
ADAMTS13 antigen. A variety of peptide substrates derived from
the VWF A2 domain can be used to assay ADAMTS13 activity5;

An International Standard (IS) plasma for ADAMTS13 is available
(12/252; NIBSC, South Mimms, UK)

53

their specificity can be checked by a negative control containing

and is calibrated for activity

10 mmol/L EDTA. When performing assays, the operator should be

and antigen. This should be used as the primary calibrant for com-

aware that many reagent and plasma additives (EDTA, protease in-

mercial calibrants and local assay standards should be traceable to

hibitors and surfactants) as well as certain therapeutic materials can

the IS, with results being reported as International Units. Irrespective

potentially interfere with assay performance, especially the FRET-

of which anticoagulant, or if serum is used, the assay calibrant should

based assays.

be of the same type as the sample, for example use pooled citrated

Bilirubin levels >100 µmol/L (although rarely seen in acute TTP

plasma standard for citrated samples.3 It should be noted that the

plasmas) can reduce ADAMTS13 activity in the FRETS VWF-73

IS calibration is derived from lyophilized citrated plasma and so dis-

assay due to fluorescence quenching at the emission wavelength

crepancy may occur if the test plasma is prepared using a different

(450 nm).54 This results in reduced baseline fluorescence measure-

anticoagulant. The IS has not been assessed with modified assays;

ment and apparent ADAMTS13 reduction. The CBA and chromo-

for example minimally diluted plasma and varying ionic strength. In

genic peptide ELISA are not affected by bilirubin, which is removed

the absence of IS availability, results should be reported as percent-

in the washing stages. However, in vitro studies suggest that un-

age of pooled normal plasma. Some commercial calibrants are only

conjugated bilirubin may have a direct, dose-dependent inhibitory

suitable for use in the manufacturer's kit and may give false low or

effect on cleavage of both peptidyl and native VWF substrates by

high levels when used in other assay techniques, due to additives

ADAMTS13.55 The influence of bilirubin may sometimes be reduced

and buffering. Care should be taken with the use of stabilizers (fre-

by using higher sample dilution, but this is limited by ADAMTS13

quently used in lyophilization of plasma), to avoid pH changes and

activity level and the detection limit. Bilirubin oxidase has been

alteration of the ionic environment, which can have marked effects

employed56 to avoid quenching, but the method has not been fully

on ADAMTS13 function.

validated for use with clinical samples. Some samples (with no visible icterus) exhibit low baseline fluorescence in FRET assays, so it is

3.5 | Sensitivity

likely that certain other substances or therapeutic agents may influence the assay.
Haemoglobin has been shown to bind specifically to the VWF

ADAMTS13 assay sensitivity can be attributed to several factors, in-

A2 domain and prevent cleavage by ADAMTS13,57,58 using both full-

cluding the substrate type, assay method, instrument, buffer condi-

length VWF and the VWF A2 domain as substrates. The effect of

tions and volume of plasma. ADAMTS13 has maximal activity at low

haemoglobin on shorter VWF peptide substrates, such as those used

pH (pH 6) and low ionic strength (zero NaCl) as opposed to pH 7.4

in the FRETS and chromogenic assays, is unclear. However, 2 g/L Hb

and salt concentrations similar to those in plasma (150 mmol/L NaCl).

reduced ADAMTS13 activity by ~10% in a FRETS-rVWF71 assay,3

Generally, VWF peptide-based assays are more sensitive than those

which could have a significant impact on patient management.

using multimeric VWF digest analysis. The first generation FRETbased assay sensitivity was limited (~3%-5% of normal ADAMTS13
activity),30 whereas more recent, optimized FRETS, chromogenic ac-

3.7 | Antigen assays

tivity ELISA and microparticle-based assays have a limit of quantitation of 0.2-0.3 IU/dL (Table 1). Sensitivity at very low ADAMTS13

Immunoblotting procedures and ELISA assays have been used for

levels ≤5 IU/dL for FRET-based assays can be obscured by baseline

ADAMTS13 antigen measurement and the latter is the method of

autofluorescence, temperature fluctuations and photobleaching as-

choice in the clinical diagnostic laboratory when an assay is indi-

sociated with fluorophores.

cated. There are a variety of commercial kits and numerous poly-

New FRET assays, utilizing a rVWF71 polypeptide correspond-

clonal and monoclonal antibodies available for assays. The capture

ing to VWF Gln 1599-Arg1668, containing mutations N1610C and

and detection antibody selection is critical as monoclonal anti-

K1617R, as well as an N-terminal Gly, are more sensitive and appear

bodies directed against the central domains of the protein may
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detect truncated forms and full-length ADAMTS13, while antibod-

the FRET-based assay. A flow-based assay for ADAMTS13 inhibitor

ies directed against the C-terminus may underestimate functional

assessment has also been described.61

ADAMTS13 molecules.

The mixing test inhibitor methods are prone to errors because
of plasma manipulation and dilution of patient plasma with PNP

3.8 | Antibody and inhibitor assays

limits the sensitivity. Dilution could potentially alter the equilibrium between free and bound antibody. Bethesda type assays of
ADAMTS13 inhibition may be problematic due to the variability

ADAMTS13 autoantibody assays demonstrate the presence of spe-

in antibody epitope specificity, affinity and reaction kinetics be-

cific immunoglobulins and are detected in iTTP. Depending on the

tween patients. Standardization and variability were improved

ADAMTS13 domain specificity of the immunoglobulins, they may

when minimally diluted plasma and conditions close to physiologic

or may not inhibit the proteolytic activity. Inhibitory antibodies can

were used. FRETS-rVWF71 was ~2.5-fold more sensitive for in-

be demonstrated in mixing tests and Bethesda type assays. Non-

hibitory autoantibodies than FRETS-VWF73 using recommended

neutralizing antibodies can influence ADAMTS13 survival in the

protocols. 3

circulation and are clinically relevant. Autoantibody assays, where
available, are therefore preferred.

Sporadic, weak antibodies may sometimes be detected and may
be absent when a fresh sample is subsequently obtained. When
antibody concentrations are high, it may be difficult to determine

3.8.1 | Autoantibody assays

an exact antibody level, as the dilution curve may be nonparallel
with the calibration curve. This can arise for several reasons: in acquired TTP, there are often a variety of antibodies present, directed

Western blotting, immunocapture and ELISA assays for determina-

against epitopes on the spacer domain, the thrombospondin-like

tion of ADAMTS13 autoantibody levels have been described,59,60

repeats and other domains; these may vary in avidity and concen-

but ELISA methods for immunoglobulin (Ig) G class autoantibodies

tration, so that each antibody type is more or less pronounced in

are most widely used in clinical laboratories. The calibration of these

its effect depending on the dilution used; the reaction kinetics may

assays, their reporting units and cut-off values vary; the results may

vary between antibodies with different specificities and between

not be interchangeable.

patients; sample dilution may cause antigen:antibody complex
dissociation.

3.8.2 | Inhibitor tests

There is currently no IS or reference material for ADAMTS13 antibody and inhibitor assays, meaning that numerical results are difficult to compare between different assay types.

Patient plasma is heated at 56°C for at least 30 minutes (to inactivate
ADAMTS13 and other haemostasis proteins, while leaving IgG unaffected), centrifuged to remove any precipitated protein and doubling
dilutions are incubated with untreated pooled normal plasma (PNP),

4 | VA LI DATI O N O R V E R I FI C ATI O N O F
A S SAY PE R FO R M A N C E

as a source of ADAMTS13, for 1 hour at 37°C. A control comprising
heat-treated normal control plasma or buffer and untreated PNP is

FRETS assays (which are often used as reference methods in major

incubated in parallel. After incubation, the residual ADAMTS13 ac-

haemostasis laboratories) are mainly developed in-house and

tivity is measured in the patient and control samples. If an IgG inhibi-

are not certified by regulatory bodies (in vitro diagnostic device

tor is present in the patient sample, the ADAMTS13 activity in the

registration (CE mark) in the European Union and US Food and

test sample will be lower than the control. In this case, the incubated

Drug Administration). Commercial kits including the most widely

dilutions of heat-treated patient plasma are assayed to determine

used chromogenic activity ELISA method have regulatory body

inhibitor potency in a Bethesda type assay. Some methods do not

approval in certain countries. Where they do not, or if tests are

utilize heat treatment and are therefore potentially sensitive to other

modified (eg use of bilirubin oxidase), they must be considered as a

types of inhibitor (eg anti-ADAMTS13 IgM). Anti-ADAMTS13 IgG is

laboratory-developed test (LDT). ICSH recognizes that there is no

thought to be the most clinically significant immunoglobulin class in

universal definition of an LDT and it is therefore the responsibility

acquired TTP and heating makes the mixing test more specific, but

of the individual laboratory/institution to decide whether a test

adds a technical step and prolongs the analytical time. Assays based

system constitutes a LDT and to implement a validation procedure

on inhibition of rVWF71 are very sensitive to inhibitory antibodies

meeting their local regulatory requirements. This might include as-

but are not widely used.3

sessment of linear range, sensitivity limits, comparability, and pre-

The effects of different incubation temperatures and different

cision, or require more extensive investigation/documentation. 62

assays for measuring residual activity have recently been inves-

After the validation of assays, a verification phase should be car-

tigated, 23 showing a good correlation between FRET-based and

ried out before clinical implementation, to ensure that the assay

CBA-based inhibitor assays, although the pre-incubation at 37°C

is consistently producing acceptable results. This may be per-

causes a reduction of plasma ADAMTS13 activity when tested in

formed by comparison with another laboratory and participation
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in external quality assurance (EQA) schemes. The uncertainty of

• Rapid point of care assays may have utility as screening methods

measurement (UOM) should be estimated by each laboratory to

or “out of hours” emergency tests, but there is currently limited

aid in the interpretation of borderline results. Long-term internal

performance data.

quality control (IQC) data are used at each IQC level, to determine

• Every calibrator should be traceable to the International Standard

the mean and standard deviation (SD), expressed with 95% confi-

Plasma (12/252) for assaying ADAMTS13 activity in citrated

dence (±1.96 SD).

63

Thus, a sample with 0.20 IU/dL activity and

SD 0.03 would give UOM ± 0.04 IU/dL, indicating a true value
between 0.14 and 0.26 IU/dL.

plasma samples.
• When reporting results: indicate the type of assay performed and
use the correct units (eg IU/dL) for activity and antigen assays. If
calibrants traceable to the IS are not available, use percentage of

4.1 | Internal quality control, external
quality assessment

pooled normal plasma. State the reference range for the method.
• High and low activity controls should be included in each assay
run. Do not use commercial controls in methods other than those
intended for their use.

Some commercial kits provide normal and abnormal control samples,

• Protocols should be validated after any modification.

and these should be run with every batch of tests to provide IQC. If

• If gross icterus interferes in some FRET assay methods, the prob-

these are not available, or if additional IQC is required, local controls

lem can sometimes be resolved by assaying at a higher dilution,

using aliquots of plasma samples that have previously been assigned

treatment with bilirubin oxidase, or using a chromogenic activity

a potency and an acceptable performance range can be included.

ELISA. A comment regarding potential assay interference should

Ideally, these should have been originally collected in the same way

be added to the laboratory report.

as test samples. Performance should be monitored over a range of

• If artefactual, in vitro haemolysis is likely (eg secondary to difficult

potencies. Commercial control samples should only be used in the

venipuncture or use of a small gauge needle), fresh blood samples

methods for which they were designed, unless formal validation is

should be obtained. If this is not possible, a comment regarding

performed, as differences in the buffer environment may influence

potential assay interference should be added to the laboratory

their performance.

report.

The United Kingdom National External Quality Assessment

• Where assay results do not match the clinical picture, or congen-

Service, the ECAT Foundation, the College of American Pathologists

ital TTP is suspected and ADAMTS13 activity results are normal

and the North American Specialized Coagulation Laboratory

or only show a mild reduction, collagen-binding assays should be

Association, all provide external quality assessment studies for
ADAMTS13 assays, with several proficiency testing surveys each
year.

considered.
• If decreased ADAMTS13 activity (<20 IU/dL) is detected in a new
patient, an ADAMTS13 antibody assay or inhibitor test should be
performed. If the results do not match the clinical picture, poten-

4.2 | Criteria for validation of each assay run

tial EDTA contamination should be considered and where possible, fresh blood samples obtained.
• Wherever possible, use the same ADAMTS13 assay when study-

A calibration curve should be performed with each batch of tests

ing a patient longitudinally to manage treatment.

to avoid reagent and analyser variability. Some activity assay methods may be particularly temperature sensitive. IQC values should
be within their target range. Test results should be within the linear

5 | C LI N I C A L U TI LIT Y O F A S SAYS

portion of the calibration curve; if they have levels above this range,
they should be repeated at higher dilution; if below the range, they

Due to the rarity of TTP, ADAMTS13 assays are not widely per-

must be reported as less than the lower limit of quantification. In

formed and remain mainly confined to specialized laboratories.

kinetic assays, the baseline readings should be checked and very low

However, recent advances in the development of ADAMTS13 assays

or high values may indicate an analytical problem.

and recognized importance of ADAMTS13 testing in TMA differential diagnosis indicate that there is an urgent need for a timely and
reliable ADAMTS13 result for the clinician. Clinical scoring systems

4.3 | Consensus recommendations on assays for
ADAMTS13, autoantibodies and inhibitors

<176 µmol/L, international normalized ratio <1.5, mean corpuscular

• Functional FRET-based assays or chromogenic activity ELISA

plantation) may help clinicians decide on the urgency of ADAMTS13

such as the PLASMIC score64 (platelets <30 × 109/L, creatinine
volume <90 fL, evidence of haemolysis, no cancer or organ trans-

methods are recommended as front line assays as they are sensitive, show good precision and are simpler to use, being completed
in a few hours.

testing and the likelihood of a positive TTP diagnosis.
When a patient presents with a clinical scenario and blood film of
suspected TMA (Fig. 1), deficiency of ADAMTS13 activity of <10 IU/dL
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varies between laboratories depending on the assay and reagents

Clinical suspicion of TMA*

used and the limit of normality varies both numerically and in the
units used. If no significant ADAMTS13 antibody is found, hereditary deficiency of ADAMTS13 is suspected and replacement ther-

ADAMTS13 acvity
≤ 10%
TTP

•
•

•
ADAMTS13 anbody
Posive
Immune-mediated TTP
(iTTP)

apy with plasma or ADAMTS13 containing FVIII concentrates may

≥ 10%

†

be considered rather than immunosuppression.70 In these cases,
IA-HUS
CM-HUS
Other
secondary
causes of
TMA

Negave

ADAMTS13 genetic testing is helpful to confirm the diagnosis of
cTTP.71 ADAMTS13 phenotypic and genetic testing of the proband's
parents and siblings is suggested to further confirm the hereditary
nature of TTP, especially for compound heterozygous mutations and
for genetic counselling.
Precision of the ADAMTS13 activity assay around the 10 IU/dL

Congenital TTP
(cTTP)

cut-off level and clinical interpretation of the result is still problematic, leading to a wide variation in clinical decisions and management.

F I G U R E 1 ADAMTS13 testing for the diagnosis of TTP and
other TMA. *Based on clinical assessment including Clinical Gestalt,
PLASMIC score, laboratory investigation (haemoglobin, platelet
count, fragments, and creatinine level). †High titre ADAMTS13
antibody (ELISA) or functional inhibitor of ADAMTS13 activity
measured by Bethesda assay. CM-HUS, complement mediated
haemolytic uremic syndrome; IA-HUS, infection associated
haemolytic uremic syndrome; TMA, thrombotic microangiopathy;
TTP, thrombotic thrombocytopenic purpura

An indeterminate range of between 10 and 20 IU/dL activity necessitates repeat assay, and it is more likely to be significant for TTP
diagnosis if a high level of ADAMTS13 autoantibody is also detected.
Interpreting the clinical significance of an isolated ADAMTS13 antibody result is challenging because of the limited data defining
abnormal levels and arbitrary normal cut-off values depending on
the laboratory, leading to the misdiagnoses of a detectable but not
pathological ADAMTS13 antibody. Furthermore, standardization of
the method and nomenclature of the ADAMTS13 Bethesda assay

(and particularly <5 IU/dL) is diagnostic for TTP.8 Levels greater than

are lacking. Up to 25% of iTTP patients have autoantibodies that do

10 IU/dL suggest another diagnosis depending on the clinical circum-

not neutralize the ADAMTS13 activity, but they are thought to be

stances and include consideration of HUS (both Shiga toxin or aHUS)

pathological by removal of ADAMTS13 through an immune complex

and secondary TMA.

or other clearance mechanism.72

The turnaround time for ADAMTS13 activity results varies con-

Around 30%-50% of iTTP patients have exacerbation (falling

siderably depending on local practice and logistic reasons, so often

platelet count to below the normal range, an increased LDH level

PEX and prednisolone treatment is initiated early while awaiting

and the need to restart PEX within 30 days of the last exchange)

the assay result. However, PEX is less effective in TMA patients

or relapse (falling platelet count below the normal range, with

with ADAMTS13 >10 IU/dL who do not have TTP,11 so timely ac-

or without clinical symptoms, more than 30 days after stopping

cess to an assay avoids the cost, inconvenience and side effects of

PEX and requiring therapy) with the risk of exacerbation or re-

this ongoing, unnecessary intervention. In addition, access to new

lapse related to persisting ADAMTS13 deficiency of <10 IU/dL

TMA therapies such as caplacizumab (a nanobody that blocks VWF

and detectable autoantibodies at the end of plasma exchange

binding to platelet glycoprotein Ib)65 and rituximab (an immunosup-

despite a normal platelet count, or during disease remission,

pressant anti-CD20 antibody)66,67 for acquired TTP and eculizumab

respectively. 60,70,73,74

68

is further motivation

Frontline rituximab in acute iTTP and pre-emptive rituximab in

for rapid, widely available screening of ADAMTS-13 activity. This

iTTP patients in remission with persisting low ADAMTS13 activity

could be achieved with recently reported automated chemilu-

have been considered, but its use, particularly in patients with a first

minescent immunoassay34-36 or rapid POC tests. 38 Subsequent

event is debated as not all iTTP patients experiencing a first event

confirmation of an abnormal result with an ADAMTS13 FRET or

will relapse and not all iTTP patients who have a low ADAMTS13

activity ELISA assay may be required until these newer, rapid as-

activity during remission will relapse. Caplacizumab, which should

says are further validated. Ideally, the first sample should be taken

ideally be started in the early phase of the acute TTP event for

prior to initiation of plasma-based therapy to avoid interference of

maximum benefit, was also shown to prevent exacerbation in iTTP

donor plasma ADAMTS13 or dilution of the anti-ADAMTS13 au-

patients achieving clinical response, but still presenting severely re-

toantibody. However, in a series of 18 acquired TTP patients fol-

duced ADAMTS13 activity, supporting its extended use until the un-

lowed throughout daily PEX therapy, >75% still showed <10 IU/

derlying autoimmune disease is resolved. Thus, the appropriate use

dL ADAMTS13 activity immediately before the fourth exchange

of both rituximab and caplacizumab in iTTP demands the availability

(a C5 complement inhibitor) for CM-HUS

procedure.

69

of accurate and timely ADAMTS13 testing.

Differentiating between cTTP and iTTP relies upon the detec-

Mortality is also increased in iTTP patients with the highest IgG

tion or absence of an ADAMTS13 autoantibody or inhibitor.13,70

ADAMTS13 antibody and lowest ADAMTS 13 antigen level,75 per-

The determination of a clinically significant positive IgG antibody

haps suggesting increased clearance or immune complex binding of

694
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circulating ADAMTS13 antigen and these patients may especially

AC K N OW L E D G E M E N T S

benefit from new therapies. ADAMTS13 antigen levels are not rou-

All authors were part of the ICSH ADAMTS13 Assays Working

tinely measured and have little clinical utility in the absence of ac-

Group chaired by IM and all contributed to the design, drafting and

tivity assays24; further work is required to understand the clinical

editing of this document.

significance of this finding.
It is apparent there is an urgent need for standardizing

C O N FL I C T O F I N T E R E S T

ADAMTS13 testing for the different clinical situations of the new

ICSH is a “not for profit” organization. I Mackie and S Machin are

TMA diagnosis, whether it is iTTP, cTTP, CM-HUS, TTP monitoring
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or prediction of TTP relapse.
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5.1 | Consensus recommendations on clinical
utility of assays
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• ADAMTS13 activity <10 IU/dL is diagnostic for TTP in patients
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presenting with a clinical scenario and blood film consistent with
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• An alternative diagnosis and repeat ADAMTS13 assay should be
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considered in TMA patients presenting with an indeterminate
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• Alternative diagnosis/therapy should be considered in patients
with an ADAMTS13 activity >10 IU/dL, especially when >20 IU/
dL, as they rarely respond to PEX.
• The overall clinical picture/treatment of the patient should al-
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ways be reviewed with close interaction with clinicians. This is
important to avoid unnecessary tests and to ensure that appro-
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